Benjamin P. Linas, MD

Associate Professor, Medicine

Benjamin Linas
617.414.5238

Biography

Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.

Other Positions

  • Associate Professor, Epidemiology, Boston University School of Public Health

Education

  • New York University School of Medicine, MD
  • Harvard School of Public Health, MPH
  • Yale University, BA

Publications

  • Published on 5/16/2019

    Assoumou SA, Tasillo A, Vellozzi C, Yazdi GE, Wang J, Nolen S, Hagan L, Thompson W, Randall LM, Strick L, Salomon JA, Linas BP. Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons. Clin Infect Dis. 2019 May 16. PMID: 31095676.

    Read at: PubMed
  • Published on 5/16/2019

    Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis. 2019 May 16. PMID: 31095683.

    Read at: PubMed
  • Published on 5/10/2019

    Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy. 2019 May 10. PMID: 31085063.

    Read at: PubMed
  • Published on 5/8/2019

    Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, Beckwith CG, Linas BP, Walley AY. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019 May 08; 200:59-63. PMID: 31100636.

    Read at: PubMed
  • Published on 5/3/2019

    Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019 May 03; 200:34-39. PMID: 31082666.

    Read at: PubMed
  • Published on 3/14/2019

    Jones EA, Linas BP, Truong V, Burgess JF, Lasser KE. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program. PLoS One. 2019; 14(3):e0213745. PMID: 30870475.

    Read at: PubMed
  • Published on 2/21/2019

    Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, Kamkamidze G, Krajden M, Loarec A, Njouom R, Nguyen KV, Shiha G, Soliman R, Solomon SS, Tsertsvadze T, Denkinger CM, Linas B. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. J Hepatol. 2019 Feb 21. PMID: 30797050.

    Read at: PubMed
  • Published on 2/1/2019

    Cohen GH, Tamrakar S, Lowe S, Sampson L, Ettman C, Kilpatrick D, Linas BP, Ruggiero K, Galea S. Improved social services and the burden of post-traumatic stress disorder among economically vulnerable people after a natural disaster: a modelling study. Lancet Planet Health. 2019 Feb; 3(2):e93-e101. PMID: 30797416.

    Read at: PubMed
  • Published on 2/1/2019

    Tasillo A, Eftekhari Yazdi G, Nolen S, Schillie S, Vellozzi C, Epstein R, Randall L, Salomon JA, Linas BP. Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care. Obstet Gynecol. 2019 Feb; 133(2):289-300. PMID: 30633134.

    Read at: PubMed
  • Published on 1/25/2019

    Shelton BA, Berdahl G, Sawinski D, Linas BP, Reese PP, Mustian MN, Reed RD, MacLennan PA, Locke JE. Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: Pre- vs posttransplant. Am J Transplant. 2019 Jun; 19(6):1806-1819. PMID: 30589503.

    Read at: PubMed

View 73 more publications: View full profile at BUMC

View all profiles